Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

CLL

John C. Byrd, M.D.
Will the word "cure" be used for patients with chronic lymphocytic leukemia (CLL)?
Brian Koffman, M.D.C.M
Brian Koffman is a family physician who used his own CLL diagnosis to start a group that informs other patients and their loved ones.
Nicole Lamanna, M.D., provides insight on how the management of chronic lymphocytic leukemia (CLL) might progress as new therapeutic agents are introduced or matched together.
In the setting of relapsed chronic lymphocytic leukemia, Nicole Lamanna, M.D., considers the patient and disease factors that affect her selection of therapy.
 
In the context of therapeutic management of chronic lymphocytic leukemia (CLL), Nicole Lamanna, M.D., offers advice regarding lifestyle modifications that may improve outcomes for patients.
Nicole Lamanna, M.D., reflects on the factors that influence her decision-making process while selecting an approved therapy or clinical trial for patients with chronic lymphocytic leukemia (CLL).
The optimal length of time to wait to initiate treatment for patients with chronic lymphocytic leukemia (CLL), as well as the length of time to remain on treatment, are described by Nicole Lamanna, M.D.
With regard to cytogenetic testing, molecular testing, and imaging, Nicole Lamanna, M.D., outlines what testing should be completed alongside a diagnosis of chronic lymphocytic leukemia (CLL).
Kristie L. Kahl
The combination use of Imbruvica (ibrutinib) with Rituxan (rituximab) significantly improved survival outcomes compared with standard of care in younger patients with chronic lymphocytic leukemia (CLL).
Chuck Pagano
Former NFL coach discusses how cancer motivated him to appreciate life.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other